Editas Medicine (EDIT) Income from Continuing Operations (2015 - 2025)
Editas Medicine (EDIT) reported Income from Continuing Operations of 25116000.0 for Q3 2025, up 59.58% year-over-year from 15738914.2 in Q3 2024, and up 51.21% on a QoQ basis from 51477000.0 in Q2 2025.
Editas Medicine (EDIT) has 11 years of Income from Continuing Operations data on file, last reported at 25116000.0 in Q3 2025.
- Quarterly Income from Continuing Operations rose 59.58% year-over-year to 25116000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 197648000.0 (up 6.13% YoY) and the FY2024 annual result came in at 237090000.0, down 56.38% from the prior year.
- Income from Continuing Operations climbed to 25116000.0 in Q3 2025 per EDIT's latest filing, from 51477000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 18860000.0 in Q4 2023 and bottomed at 75663000.0 in Q1 2025.
- The 5-year median for Income from Continuing Operations is 51477000.0 (2025), against an average of 50206842.11.
- The widest annual swing landed in 2021, when Income from Continuing Operations slumped 524.32%; it then surged 68.95% in 2023.
- Tracing EDIT's Income from Continuing Operations over 5 years: stood at 41435000.0 in 2021, then plunged by 46.58% to 60734000.0 in 2022, then surged by 68.95% to 18860000.0 in 2023, then plunged by 140.68% to 45392000.0 in 2024, then surged by 44.67% to 25116000.0 in 2025.
- Per Business Quant, the three latest EDIT Income from Continuing Operations figures stand at 25116000.0 (Q3 2025), 51477000.0 (Q2 2025), and 75663000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -25.12 Mn |
| Jun 30, 2025 | -51.48 Mn |
| Mar 31, 2025 | -75.66 Mn |
| Dec 31, 2024 | -45.39 Mn |
| Sep 30, 2024 | -62.14 Mn |
| Jun 30, 2024 | -67.61 Mn |
| Mar 31, 2024 | -61.96 Mn |
| Dec 31, 2023 | -18.86 Mn |
| Sep 30, 2023 | -45.02 Mn |
| Jun 30, 2023 | -40.28 Mn |
| Mar 31, 2023 | -47.45 Mn |
| Dec 31, 2022 | -60.73 Mn |
| Sep 30, 2022 | -55.73 Mn |
| Jun 30, 2022 | -53.69 Mn |
| Mar 31, 2022 | -50.28 Mn |
| Dec 31, 2021 | -41.44 Mn |
| Sep 30, 2021 | -39.10 Mn |
| Jun 30, 2021 | -55.26 Mn |
| Mar 31, 2021 | -56.75 Mn |
| Dec 31, 2020 | -65.64 Mn |
| Sep 30, 2020 | 9.22 Mn |
| Jun 30, 2020 | -30.75 Mn |
| Mar 31, 2020 | -45.06 Mn |
| Dec 31, 2019 | -37.78 Mn |
| Sep 30, 2019 | -32.91 Mn |
| Jun 30, 2019 | -33.72 Mn |
| Mar 31, 2019 | -29.21 Mn |
| Dec 31, 2018 | -25.05 Mn |
| Sep 30, 2018 | -15.23 Mn |
| Jun 30, 2018 | -38.88 Mn |
| Mar 31, 2018 | -31.12 Mn |
| Sep 30, 2017 | -26.80 Mn |
| Jun 30, 2017 | -26.56 Mn |
| Mar 31, 2017 | -31.24 Mn |
| Dec 31, 2016 | -39.34 Mn |
| Sep 30, 2016 | -21.02 Mn |
| Jun 30, 2016 | -19.05 Mn |
| Mar 31, 2016 | -17.72 Mn |
| Dec 31, 2015 | -12.41 Mn |
| Sep 30, 2015 | -7.43 Mn |
| Jun 30, 2015 | -10.43 Mn |
| Mar 31, 2015 | -5.19 Mn |